Hepatitis C

Sleisenger and Fordtran’s Gastrointestinal and Liver Disease- 2 Volume Set: Pathophysiology, Diagnosis, Management, Expert Consult Premium Edition - Enhanced Online Features and Print

Volumn , Issue , 2010, Pages 1313-1335

  O’Leary, Jacqueline G ^a   Davis, Gary L ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79952380518     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-6189-2.00079-2     Document Type: Chapter

References (295)

1. Armstrong GL., Wasley A., Simard EP., et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 Ann Intern Med 144 2006 705-714(Ref 1.)
2. Bruno S., Stroffolini T., Colombo M., et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: A retrospective study Hepatology 45 2007 579-587(Ref 158.)
3. Everson GT., Trotter J., Forman L., et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy Hepatology 42 2005 255-262(Ref 224.)
4. Fried MW., Shiffman ML., Reddy KR., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975-982(Ref 6.)
5. Mangia A., Minerva N., Bacca D., et al. Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial Hepatology 47 2008 43-50(Ref 246.)
6. Manning DS., Afdhal NH Diagnosis and quantitation of fibrosis Gastroenterology 134 2008 1670-1681(Ref 138.)
7. Manns MP., McHutchison JG., Gordon SC., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial Lancet 358 2001 958-965(Ref 7.)
8. Missiha SB., Ostrowski M., Heathcote EJ Disease progression in chronic hepatitis C: Modifiable and nonmodifiable factors Gastroenterology 134 2008 1699-1714(Ref 157.)
9. Poordad F., Reddy KR., Martin P Rapid virologic response: A new milestone in the management of chronic hepatitis C Clin Infect Dis 46 2008 78-84(Ref 232.)
10. Powell EE., Jonsson JR., Clouston AD Steatosis: Co-factor in other liver diseases Hepatology 42 2005 5-13(Ref 178.)
11. Sangiovanni A., Prati GM., Fasani P., et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients Hepatology 43 2006 1303-1310(Ref 154.)
12. Shiffman ML., Salvatore J., Hubbard S., et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha Hepatology 46 2007 371-379(Ref 237.)
13. Shiffman ML., Suter F., Bacon BR., et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3 N Engl J Med 357 2007 124-134(Ref 241.)
14. Strader DB., Wright T., Thomas DL., Seeff LB Diagnosis, management, and treatment of hepatitis C Hepatology 39 2004 1147-1171(Ref 144.)
15. Wiesner RH., Sorrell M., Villamil F Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C Liver Transpl 9 2003 S1-S9(Ref 191.)
16. Armstrong GL., Wasley A., Simard EP., et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 Ann Intern Med 144 2006 705-714.
17. Alter MJ., Kruszon-Moran D., Nainan OV., et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 N Engl J Med 341 1999 556-562.
18. Davis GL., Albright JE., Cook SF., Rosenberg DM Projecting future complications of chronic hepatitis C in the United States Liver Transpl 9 2003 331-338.
19. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium J Viral Hepat 6 1999 35-47.
20. Wise M., Bialek S., Finelli L., et al. Changing trends in hepatitis C-related mortality in the United States, 1995-2004 Hepatology 47 2008 1128-1135.
21. Fried MW., Shiffman ML., Reddy KR., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975-982.
22. Manns MP., McHutchison JG., Gordon SC., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial Lancet 358 2001 958-965.
23. Yu X., Qiao M., Atanasov I., et al. Cryo-electron microscopy and three-dimensional reconstructions of hepatitis C virus particles Virology 367 2007 126-134.
24. Maillard P., Krawczynski K., Nitkiewicz J., et al. Nonenveloped nucleocapsids of hepatitis C virus in the serum of infected patients J Virol 75 2001 8240-8250.
25. Robertson B., Myers G., Howard C., et al. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy Arch Virol 143 1998 2493-2503.
26. Penin F., Dubuisson J., Rey FA., et al. Structural biology of hepatitis C virus Hepatology 39 2004 5-19.
27. Dubuisson J Hepatitis C virus proteins World J Gastroenterol 13 2007 2406-2415.
28. Reed KE., Rice CM Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties Curr Top Microbiol Immunol 242 2000 55-84.
29. Lerat H., Hollinger FB Hepatitis C virus (HCV) occult infection or occult HCV RNA detection? J Infect Dis 189 2004 3-6.
30. Pham TN., King D., Macparland SA., et al. Hepatitis C virus replicates in the same immune cell subsets in chronic hepatitis C and occult infection Gastroenterology 134 2008 812-822.
31. Cormier EG., Tsamis F., Kajumo F., et al. CD81 is an entry coreceptor for hepatitis C virus Proc Natl Acad Sci U S A 101 2004 7270-7274.
32. Zeisel MB., Koutsoudakis G., Schnober EK., et al. Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81 Hepatology 46 2007 1722-1731.
33. Evans MJ., von Hahn T., Tscherne DM., et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry Nature 446 2007 801-805.
34. Barth H., Schafer C., Adah MI., et al. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate J Biol Chem 278 2003 41003-41012.
35. Agnello V., Abel G., Elfahal M., et al. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor Proc Natl Acad Sci U S A 96 1999 12766-12771.
36. Cormier EG., Durso RJ., Tsamis F., et al. L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus Proc Natl Acad Sci U S A 101 2004 14067-14072.
37. Bartosch B., Verney G., Dreux M., et al. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies J Virol 79 2005 8217-8229.
38. Bartosch B., Dubuisson J., Cosset FL Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes J Exp Med 197 2003 633-642.
39. Honda M., Ping LH., Rijnbrand RC., et al. Structural requirements for initiation of translation by internal ribosome entry within genome-length hepatitis C virus RNA Virology 222 1996 31-42.
40. Ji H., Fraser CS., Yu Y., et al. Coordinated assembly of human translation initiation complexes by the hepatitis C virus internal ribosome entry site RNA Proc Natl Acad Sci U S A 101 2004 16990-16995.
41. Egger D., Wolk B., Gosert R., et al. Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex J Virol 76 2002 5974-5984.
42. Elazar M., Liu P., Rice CM., Glenn JS An N-terminal amphipathic helix in hepatitis C virus (HCV) NS4B mediates membrane association, correct localization of replication complex proteins, and HCV RNA replication J Virol 78 2004 11393-11400.
43. Gosert R., Egger D., Lohmann V., et al. Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons J Virol 77 2003 5487-5492.
44. Bartenschlager R., Frese M., Pietschmann T Novel insights into hepatitis C virus replication and persistence Adv Virus Res 63 2004 71-180.
45. Tanaka Y., Shimoike T., Ishii K., et al. Selective binding of hepatitis C virus core protein to synthetic oligonucleotides corresponding to the 5′ untranslated region of the viral genome Virology 270 2000 229-236.
46. Mizuno M., Yamada G., Tanaka T., et al. Virion-like structures in HeLa G cells transfected with the full-length sequence of the hepatitis C virus genome Gastroenterology 109 1995 1933-1940.
47. Sakai A., Claire MS., Faulk K., et al. The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences Proc Natl Acad Sci U S A 100 2003 11646-11651.
48. Steinmann E., Penin F., Kallis S., et al. Hepatitis C Virus p7 protein is crucial for assembly and release of infectious virions PLoS Pathog 3 2007 e103.
49. Walewski JL., Keller TR., Stump DD., Branch AD Evidence for a new hepatitis C virus antigen encoded in an overlapping reading frame RNA 7 2001 710-721.
50. Xu Z., Choi J., Yen TS., et al. Synthesis of a novel hepatitis C virus protein by ribosomal frameshift EMBO J 20 2001 3840-3848.
51. Branch AD., Stump DD., Gutierrez JA., et al. The hepatitis C virus alternate reading frame (ARF) and its family of novel products: The alternate reading frame protein/F-protein, the double-frameshift protein, and others Semin Liver Dis 25 2005 105-117.
52. Wang Y., Kato N., Jazag A., et al. Hepatitis C virus core protein is a potent inhibitor of RNA silencing-based antiviral response Gastroenterology 130 2006 883-892.
53. Hosui A., Ohkawa K., Ishida H., et al. Hepatitis C virus core protein differently regulates the JAK-STAT signaling pathway under interleukin-6 and interferon-gamma stimuli J Biol Chem 278 2003 28562-28571.
54. Zimmermann M., Flechsig C., La Monica N., et al. Hepatitis C virus core protein impairs in vitro priming of specific T cell responses by dendritic cells and hepatocytes J Hepatol 48 2008 51-60.
55. Jhaveri R., McHutchison J., Patel K., et al. Specific polymorphisms in hepatitis C virus genotype 3 core protein associated with intracellular lipid accumulation J Infect Dis 197 2008 283-291.
56. Banerjee S., Saito K., Ait-Goughoulte M., et al. Hepatitis C virus core protein upregulates serine phosphorylation of insulin receptor substrate-1 and impairs the downstream akt/protein kinase B signaling pathway for insulin resistance J Virol 82 2008 2606-2612.
57. Akuta N., Suzuki F., Kawamura Y., et al. Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis Hepatology 46 2007 1357-1364.
58. Bartosch B., Cosset FL Cell entry of hepatitis C virus Virology 348 2006 1-12.
59. Lorenz IC., Marcotrigiano J., Dentzer TG., Rice CM Structure of the catalytic domain of the hepatitis C virus NS2-3 protease Nature 442 2006 831-835.
60. Kim JL., Morgenstern KA., Lin C., et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide Cell 87 1996 343-355.
61. Binder M., Kochs G., Bartenschlager R., Lohmann V Hepatitis C virus escape from the interferon regulatory factor 3 pathway by a passive and active evasion strategy Hepatology 46 2007 1365-1374.
62. Li K., Foy E., Ferreon JC., et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF Proc Natl Acad Sci U S A 102 2005 2992-2997.
63. Meylan E., Curran J., Hofmann K., et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus Nature 437 2005 1167-1172.
64. Myong S., Bruno MM., Pyle AM., Ha T Spring-loaded mechanism of DNA unwinding by hepatitis C virus NS3 helicase Science 317 2007 513-516.
65. Lindenbach BD., Pragai BM., Montserret R., et al. The C terminus of hepatitis C virus NS4A encodes an electrostatic switch that regulates NS5A hyperphosphorylation and viral replication J Virol 81 2007 8905-8918.
66. Tellinghuisen TL., Marcotrigiano J., Rice CM Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase Nature 435 2005 374-379.
67. Nanda SK., Herion D., Liang TJ The SH3 binding motif of HCV [corrected] NS5A protein interacts with Bin1 and is important for apoptosis and infectivity Gastroenterology 130 2006 794-809.
68. Wang J., Tong W., Zhang X., et al. Hepatitis C virus non-structural protein NS5A interacts with FKBP38 and inhibits apoptosis in Huh7 hepatoma cells FEBS Lett 580 2006 4392-4400.
69. Enomoto N., Sakuma I., Asahina Y., et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection N Engl J Med 334 1996 77-81.
70. Bressanelli S., Tomei L., Roussel A., et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus Proc Natl Acad Sci U S A 96 1999 13034-13039.
71. Pawlotsky JM Hepatitis C virus genetic variability: pathogenic and clinical implications Clin Liver Dis 7 2003 45-66.
72. Neumann AU., Lam NP., Dahari H., et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy Science 282 1998 103-107.
73. Choo QL., Kuo G., Weiner AJ., et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome Science 244 1989 359-362.
74. Kalinina O., Norder H., Mukomolov S., Magnius LO A natural intergenotypic recombinant of hepatitis C virus identified in St. Petersburg J Virol 76 2002 4034-4043.
75. Noppornpanth S., Lien TX., Poovorawan Y., et al. Identification of a naturally occurring recombinant genotype 2/6 hepatitis C virus J Virol 80 2006 7569-7577.
76. Blatt LM., Mutchnick MG., Tong MJ., et al. Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States J Viral Hepat 7 2000 196-202.
77. Nainan OV., Alter MJ., Kruszon-Moran D., et al. Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States Gastroenterology 131 2006 478-484.
78. Wasley A., Alter MJ Epidemiology of hepatitis C: Geographic differences and temporal trends Semin Liver Dis 20 2000 1-16.
79. Kamal SM., Nasser IA Hepatitis C genotype 4: What we know and what we don’t yet know Hepatology 47 2008 1371-1383.
80. Verbeeck J., Peigue-Lafeuille H., Ross RS., et al. HCV genotype 5: Epidemiology and spread of an uncommon genotype J Clin Virol 41 2008 170-171.
81. Esteban JI., Sauleda S., Quer J The changing epidemiology of hepatitis C virus infection in Europe J Hepatol 48 2008 148-162.
82. Farci P., Shimoda A., Coiana A., et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies Science 288 2000 339-344.
83. Sobesky R., Feray C., Rimlinger F., et al. Distinct hepatitis C virus core and F protein quasispecies in tumoral and nontumoral hepatocytes isolated via microdissection Hepatology 46 2007 1704-1712.
84. Sheridan I., Pybus OG., Holmes EC., Klenerman P High-resolution phylogenetic analysis of hepatitis C virus adaptation and its relationship to disease progression J Virol 78 2004 3447-3454.
85. Weinbaum CM., Sabin KM., Santibanez SS Hepatitis B, hepatitis C, and HIV in correctional populations: A review of epidemiology and prevention AIDS 19 Suppl 3 2005 S41-S46.
86. Hyams KC., Riddle J., Rubertone M., et al. Prevalence and incidence of hepatitis C virus infection in the US military: A seroepidemiologic survey of 21, 000 troops Am J Epidemiol 153 2001 764-770.
87. Simmonds P The origin and evolution of hepatitis viruses in humans J Gen Virol 82 2001 693-712.
88. Tanaka Y., Kurbanov F., Mano S., et al. Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality Gastroenterology 130 2006 703-714.
89. Wasley A., Grytdal S., Gallagher K Surveillance for acute viral hepatitis-United States, 2006 MMWR Surveill Summ 57 2008 1-24.
90. Prati D Transmission of hepatitis C virus by blood transfusions and other medical procedures: A global review J Hepatol 45 2006 607-616.
91. Alter HJ., Houghton M Clinical Medical Research Award. Hepatitis C virus and eliminating post-transfusion hepatitis Nat Med 6 2000 1082-1086.
92. Schreiber GB., Busch MP., Kleinman SH., Korelitz JJ The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study N Engl J Med 334 1996 1685-1690.
93. Alter MJ Prevention of spread of hepatitis C Hepatology 36 2002 S93-S98.
94. Rahnavardi M., Hosseini Moghaddam SM., Alavian SM Hepatitis C in hemodialysis patients: Current global magnitude, natural history, diagnostic difficulties, and preventive measures Am J Nephrol 28 2008 628-640.
95. Lau JY., Davis GL., Brunson ME., et al. Hepatitis C virus infection in kidney transplant recipients Hepatology 18 1993 1027-1031.
96. Kelen GD., Green GB., Purcell RH., et al. Hepatitis B and hepatitis C in emergency department patients N Engl J Med 326 1992 1399-1404.
97. Sulkowski MS., Ray SC., Thomas DL Needlestick transmission of hepatitis C JAMA 287 2002 2406-2413.
98. De Carli G., Puro V., Ippolito G Risk of hepatitis C virus transmission following percutaneous exposure in healthcare workers Infection 31 Suppl 2 2003 22-27.
99. Makary MA., Al-Attar A., Holzmueller CG., et al. Needlestick injuries among surgeons in training N Engl J Med 356 2007 2693-2699.
100. Pruss-Ustun A., Rapiti E., Hutin Y Estimation of the global burden of disease attributable to contaminated sharps injuries among health-care workers Am J Ind Med 48 2005 482-490.
101. Vandelli C., Renzo F., Romano L., et al. Lack of evidence of sexual transmission of hepatitis C among monogamous couples: Results of a 10-year prospective follow-up study Am J Gastroenterol 99 2004 855-859.
102. Blackard JT., Shata MT., Shire NJ., Sherman KE Acute hepatitis C virus infection: A chronic problem Hepatology 47 2008 321-331.
103. Gibb DM., Goodall RL., Dunn DT., et al. Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission Lancet 356 2000 904-907.
104. Conte D., Fraquelli M., Prati D., et al. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15, 250 pregnant women Hepatology 31 2000 751-755.
105. Kumar RM., Shahul S Role of breast-feeding in transmission of hepatitis C virus to infants of HCV-infected mothers J Hepatol 29 1998 191-197.
106. Hwang LY., Kramer JR., Troisi C., et al. Relationship of cosmetic procedures and drug use to hepatitis C and hepatitis B virus infections in a low-risk population Hepatology 44 2006 341-351.
107. Frank C., Mohamed MK., Strickland GT., et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt Lancet 355 2000 887-891.
108. Saito T., Gale M Jr Regulation of innate immunity against hepatitis C virus infection Hepatol Res 38 2008 115-122.
109. Golden-Mason L., Rosen HR Natural killer cells: Primary target for hepatitis C virus immune evasion strategies? Liver Transpl 12 2006 363-372.
110. Racanelli V., Rehermann B Hepatitis C virus infection: When silence is deception Trends Immunol 24 2003 456-464.
111. Takaki A., Wiese M., Maertens G., et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C Nat Med 6 2000 578-582.
112. Dixon LR., Crawford JM Early histologic changes in fibrosing cholestatic hepatitis C Liver Transpl 13 2007 219-226.
113. Gane E The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients Liver Transpl 9 2003 S28-S34.
114. Lim HL., Lau GK., Davis GL., et al. Cholestatic hepatitis leading to hepatic failure in a patient with organ-transmitted hepatitis C virus infection Gastroenterology 106 1994 248-251.
115. Guo JT., Sohn JA., Zhu Q., Seeger C Mechanism of the interferon alpha response against hepatitis C virus replicons Virology 325 2004 71-81.
116. Guo JT., Zhu Q., Seeger C Cytopathic and noncytopathic interferon responses in cells expressing hepatitis C virus subgenomic replicons J Virol 77 2003 10769-10779.
117. Der SD., Zhou A., Williams BR., Silverman RH Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays Proc Natl Acad Sci U S A 95 1998 15623-15628.
118. Tseng CT., Klimpel GR Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions J Exp Med 195 2002 43-49.
119. Crotta S., Stilla A., Wack A., et al. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein J Exp Med 195 2002 35-41.
120. Foy E., Li K., Sumpter R Jr.., et al. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling Proc Natl Acad Sci U S A 102 2005 2986-2991.
121. Zhu H., Dong H., Eksioglu E., Hemming A., et al. Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system Gastroenterology 133 2007 1649-1659.
122. Della Bella S., Crosignani A., Riva A., et al. Decrease and dysfunction of dendritic cells correlate with impaired hepatitis C virus-specific CD4+ T-cell proliferation in patients with hepatitis C virus infection Immunology 121 2007 283-292.
123. Pachiadakis I., Pollara G., Chain BM., Naoumov NV Is hepatitis C virus infection of dendritic cells a mechanism facilitating viral persistence? Lancet Infect Dis 5 2005 296-304.
124. Bain C., Fatmi A., Zoulim F., et al. Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection Gastroenterology 120 2001 512-524.
125. Ward SM., Fox BC., Brown PJ., et al. Quantification and localisation of FOXP3+ T lymphocytes and relation to hepatic inflammation during chronic HCV infection J Hepatol 47 2007 316-324.
126. Bowen DG., Walker CM Adaptive immune responses in acute and chronic hepatitis C virus infection Nature 436 2005 946-952.
127. Davis GL Hepatitis C immune globulin to prevent HCV recurrence after liver transplantation: Chasing windmills? Liver Transpl 12 2006 1317-1319.
128. Orland JR., Wright TL., Cooper S Acute hepatitis C Hepatology 33 2001 321-327.
129. Santantonio T., Medda E., Ferrari C., et al. Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy Clin Infect Dis 43 2006 1154-1159.
130. Shiffman ML., Diago M., Tran A., et al. Chronic hepatitis C in patients with persistently normal alanine transaminase levels Clin Gastroenterol Hepatol 4 2006 645-652.
131. Puoti C., Castellacci R., Montagnese F., et al. Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: The Italian prospective study of the asymptomatic C carriers (ISACC) J Hepatol 37 2002 117-123.
132. Kallman J., O’Neil MM., Larive B., et al. Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection Dig Dis Sci 52 2007 2531-2539.
133. Younossi Z., Kallman J., Kincaid J The effects of HCV infection and management on health-related quality of life Hepatology 45 2007 806-816.
134. Zignego AL., Ferri C., Pileri SA., et al. Extrahepatic manifestations of Hepatitis C Virus infection: A general overview and guidelines for a clinical approach Dig Liver Dis 39 2007 2-17.
135. Kamar N., Izopet J., Alric L., et al. Hepatitis C virus-related kidney disease: An overview Clin Nephrol 69 2008 149-160.
136. Saadoun D., Rosenzwajg M., Landau D., et al. Restoration of peripheral immune homeostasis after Rituximab in mixed cryoglobulinemia vasculitis Blood 111 2008 5334-5341.
137. Ahmed MS., Wong CF Should rituximab be the rescue therapy for refractory mixed cryoglobulinemia associated with hepatitis C? J Nephrol 20 2007 350-356.
138. Giordano TP., Henderson L., Landgren O., et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus JAMA 297 2007 2010-2017.
139. de Sanjose S., Benavente Y., Vajdic CM., et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium Clin Gastroenterol Hepatol 6 2008 451-458.
140. Zuckerman E., Zuckerman T., Sahar D., et al. The effect of antiviral therapy on t(14;18) translocation and immunoglobulin gene rearrangement in patients with chronic hepatitis C virus infection Blood 97 2001 1555-1559.
141. Zignego AL., Ferri C., Giannelli F., et al. Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas Ann Intern Med 137 2002 571-580.
142. Giannelli F., Moscarella S., Giannini C., et al. Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation Blood 102 2003 1196-1201.
143. Romero-Gomez M., Fernandez-Rodriguez CM., Andrade RJ., et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C J Hepatol 48 2008 721-727.
144. Cassani F., Cataleta M., Valentini P., et al. Serum autoantibodies in chronic hepatitis C: Comparison with autoimmune hepatitis and impact on the disease profile Hepatology 26 1997 561-566.
145. Scott JD., Gretch DR Molecular diagnostics of hepatitis C virus infection: A systematic review JAMA 297 2007 724-732.
146. Pawlotsky JM Use and interpretation of virological tests for hepatitis C Hepatology 36 2002 S65-S73.
147. Sabato MF., Shiffman ML., Langley MR., et al. Comparison of performance characteristics of three real-time reverse transcription-PCR test systems for detection and quantification of hepatitis C virus J Clin Microbiol 45 2007 2529-2536.
148. van Doorn LJ., Kleter B., Stuyver L., et al. Analysis of hepatitis C virus genotypes by a line probe assay and correlation with antibody profiles J Hepatol 21 1994 122-129.
149. Scheuer PJ., Standish RA., Dhillon AP Scoring of chronic hepatitis Clin Liver Dis 6 2002 335-347 v-vi.
150. Lefkowitch JH Liver biopsy assessment in chronic hepatitis Arch Med Res 38 2007 634-643.
151. Regev A., Berho M., Jeffers LJ., et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection Am J Gastroenterol 97 2002 2614-2618.
152. Imbert-Bismut F., Ratziu V., Pieroni L., et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study Lancet 357 2001 1069-1075.
153. Manning DS., Afdhal NH Diagnosis and quantitation of fibrosis Gastroenterology 134 2008 1670-1681.
154. Schiano TD., Azeem S., Bodian CA., et al. Importance of specimen size in accurate needle liver biopsy evaluation of patients with chronic hepatitis C Clin Gastroenterol Hepatol 3 2005 930-935.
155. Wai CT., Greenson JK., Fontana RJ., et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C Hepatology 38 2003 518-526.
156. Le Calvez S., Thabut D., Messous D., et al. The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C Hepatology 39 2004 862-863.
157. Friedrich-Rust M., Ong MF., Martens S., et al. Performance of transient elastography for the staging of liver fibrosis: A meta-analysis Gastroenterology 134 2008 960-974.
158. Shaheen AA., Wan AF., Myers RP FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: A systematic review of diagnostic test accuracy Am J Gastroenterol 102 2007 2589-2600.
159. Strader DB., Wright T., Thomas DL., Seeff LB Diagnosis, management, and treatment of hepatitis C Hepatology 39 2004 1147-1171.
160. Ryder SD., Irving WL., Jones DA., et al. Progression of hepatic fibrosis in patients with hepatitis C: A prospective repeat liver biopsy study Gut 53 2004 451-455.
161. Ghany MG., Kleiner DE., Alter H., et al. Progression of fibrosis in chronic hepatitis C Gastroenterology 124 2003 97-104.
162. Freeman AJ., Dore GJ., Law MG., et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection Hepatology 34 2001 809-816.
163. Kenny-Walsh E Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group N Engl J Med 340 1999 1228-1233.
164. Levine RA., Sanderson SO., Ploutz-Snyder R., et al. Assessment of fibrosis progression in untreated Irish women with chronic hepatitis C contracted from immunoglobulin anti-D Clin Gastroenterol Hepatol 4 2006 1271-1277.
165. Wiese M., Berr F., Lafrenz M., et al. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: A 20-year multicenter study Hepatology 32 2000 91-96.
166. El-Serag HB Hepatocellular carcinoma: Recent trends in the United States Gastroenterology 127 2004 S27-S34.
167. Fattovich G., Giustina G., Degos F., et al. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients Gastroenterology 112 1997 463-472.
168. Serfaty L., Aumaitre H., Chazouilleres O., et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis Hepatology 27 1998 1435-1440.
169. Sangiovanni A., Prati GM., Fasani P., et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients Hepatology 43 2006 1303-1310.
170. Di Bisceglie AM., Everson GT., Linsay KL., et al. Prolonged antiviral therapy with peginterferon to prevent complications of advanced liver disease associated with hepatitis C: Results of the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial [abstract] Hepatology 46 2007 ALB1.
171. Manos MM., Leyden WA., Murphy RC., et al. Limitations of conventionally derived chronic liver disease mortality rates: Results of a comprehensive assessment Hepatology 47 2008 1150-1157.
172. Missiha SB., Ostrowski M., Heathcote EJ Disease progression in chronic hepatitis C: Modifiable and nonmodifiable factors Gastroenterology 134 2008 1699-1714.
173. Bruno S., Stroffolini T., Colombo M., et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: A retrospective study Hepatology 45 2007 579-587.
174. Poynard T., Ratziu V., Charlotte F., et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c J Hepatol 34 2001 730-739.
175. Bissell DM Sex and hepatic fibrosis Hepatology 29 1999 988-989.
176. Di Martino V., Lebray P., Myers RP., et al. Progression of liver fibrosis in women infected with hepatitis C: Long-term benefit of estrogen exposure Hepatology 40 2004 1426-1433.
177. Codes L., Asselah T., Cazals-Hatem D., et al. Liver fibrosis in women with chronic hepatitis C: Evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy Gut 56 2007 390-395.
178. Wiley TE., Brown J., Chan J Hepatitis C infection in African Americans: Its natural history and histological progression Am J Gastroenterol 97 2002 700-706.
179. Sterling RK., Stravitz RT., Luketic VA., et al. A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans Clin Gastroenterol Hepatol 2 2004 469-473.
180. Kim WR., Gross JB., Poterucha JJ., et al. Outcome of hospital care of liver disease associated with hepatitis C in the United States Hepatology 33 2001 201-206.
181. Rodriguez-Torres M Latinos and chronic hepatitis C: A singular population Clin Gastroenterol Hepatol 6 2008 484-490.
182. Donato F., Tagger A., Gelatti U., et al. Alcohol and hepatocellular carcinoma: The effect of lifetime intake and hepatitis virus infections in men and women Am J Epidemiol 155 2002 323-331.
183. Anand BS., Currie S., Dieperink E., et al. Alcohol use and treatment of hepatitis C virus: Results of a national multicenter study Gastroenterology 130 2006 1607-1616.
184. Harris DR., Gonin R., Alter HJ., et al. The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse Ann Intern Med 134 2001 120-124.
185. Hutchinson SJ., Bird SM., Goldberg DJ Influence of alcohol on the progression of hepatitis C virus infection: A meta-analysis Clin Gastroenterol Hepatol 3 2005 1150-1159.
186. Monto A., Patel K., Bostrom A., et al. Risks of a range of alcohol intake on hepatitis C-related fibrosis Hepatology 39 2004 826-834.
187. Pessione F., Ramond MJ., Njapoum C., et al. Cigarette smoking and hepatic lesions in patients with chronic hepatitis C Hepatology 34 2001 121-125.
188. Hezode C., Zafrani ES., Roudot-Thoraval F., et al. Daily cannabis use: A novel risk factor of steatosis severity in patients with chronic hepatitis C Gastroenterology 134 2008 432-439.
189. Gary-Bobo M., Elachouri G., Gallas JF., et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats Hepatology 46 2007 122-129.
190. Moucari R., Asselah T., Cazals-Hatem D., et al. Insulin resistance in chronic hepatitis C: Association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis Gastroenterology 134 2008 416-423.
191. Sheikh MY., Choi J., Qadri I., et al. Hepatitis C virus infection: Molecular pathways to metabolic syndrome Hepatology 47 2008 2127-2133.
192. Lonardo A., Adinolfi LE., Loria P., et al. Steatosis and hepatitis C virus: Mechanisms and significance for hepatic and extrahepatic disease Gastroenterology 126 2004 586-597.
193. Powell EE., Jonsson JR., Clouston AD Steatosis: Co-factor in other liver diseases Hepatology 42 2005 5-13.
194. Kawaguchi T., Yoshida T., Harada M., et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3 Am J Pathol 165 2004 1499-1508.
195. Hu KQ., Currie SL., Shen H., et al. Clinical implications of hepatic steatosis in patients with chronic hepatitis C: A multicenter study of U.S. veterans Dig Dis Sci 52 2007 570-578.
196. Hickman IJ., Clouston AD., Macdonald GA., et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C Gut 51 2002 89-94.
197. Sharma P., Balan V., Hernandez J., et al. Hepatic steatosis in hepatitis C virus genotype 3 infection: Does it correlate with body mass index, fibrosis, and HCV risk factors? Dig Dis Sci 49 2004 25-29.
198. Patton HM., Patel K., Behling C., et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients J Hepatol 40 2004 484-490.
199. Hanouneh IA., Feldstein AE., Lopez R., et al. Clinical significance of metabolic syndrome in the setting of chronic hepatitis C virus infection Clin Gastroenterol Hepatol 6 2008 584-589.
200. Smith BC., Gorve J., Guzail MA., et al. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C Hepatology 27 1998 1695-1699.
201. Kazemi-Shirazi L., Datz C., Maier-Dobersberger T., et al. The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C Gastroenterology 116 1999 127-134.
202. Di Bisceglie AM., Bonkovsky HL., Chopra S., et al. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: A multicenter, prospective, randomized, controlled trial Hepatology 32 2000 135-138.
203. Huang H., Shiffman ML., Cheung RC., et al. Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C Gastroenterology 130 2006 1679-1687.
204. Pradat P., Alberti A., Poynard T., et al. Predictive value of ALT levels for histologic findings in chronic hepatitis C: A European collaborative study Hepatology 36 2002 973-977.
205. Quinti I., Pierdominici M., Marziali M., et al. European surveillance of immunoglobulin safety-results of initial survey of 1243 patients with primary immunodeficiencies in 16 countries Clin Immunol 104 2002 231-236.
206. Wiesner RH., Sorrell M., Villamil F Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C Liver Transpl 9 2003 S1-S9.
207. Berenguer M., Prieto M., Rayon JM., et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation Hepatology 32 2000 852-858.
208. Thuluvath PJ., Krok KL., Segev DL., Yoo HY Trends in post-liver transplant survival in patients with hepatitis C between 1991 and 2001 in the United States Liver Transpl 13 2007 719-724.
209. McCashland T., Watt K., Lyden E., et al. Retransplantation for hepatitis C: Results of a U.S. multicenter retransplant study Liver Transpl 13 2007 1246-1253.
210. Gasink LB., Blumberg EA., Localio AR., et al. Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients JAMA 296 2006 1843-1850.
211. Wells JT., Lucey MR., Said A Hepatitis C in transplant recipients of solid organs, other than liver Clin Liver Dis 10 2006 901-917.
212. Kalia H., Lopez PM., Martin P Treatment of HCV in patients with renal failure Arch Med Res 38 2007 628-633.
213. Fabrizi F., Martin P., Dixit V., et al. Meta-analysis: Effect of hepatitis C virus infection on mortality in dialysis Aliment Pharmacol Ther 20 2004 1271-1277.
214. Fabrizi F., Dulai G., Dixit V., et al. Meta-analysis: Interferon for the treatment of chronic hepatitis C in dialysis patients Aliment Pharmacol Ther 18 2003 1071-1081.
215. Fabrizi F., Martin P., Ponticelli C Hepatitis C virus infection and renal transplantation Am J Kidney Dis 38 2001 919-934.
216. Cano O., Almenar L., Martinez-Dolz L., et al. Course of patients with chronic hepatitis C virus infection undergoing heart transplantation Transplant Proc 39 2007 2353-2354.
217. Peffault de Latour R., Levy V., Asselah T., et al. Long-term outcome of hepatitis C infection after bone marrow transplantation Blood 103 2004 1618-1624.
218. Peffault de Latour R., Asselah T., Levy V., et al. Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients Bone Marrow Transplant 36 2005 709-713.
219. Thomas DL The challenge of hepatitis C in the HIV-infected person Annu Rev Med 59 2008 473-485.
220. Salmon-Ceron D., Lewden C., Morlat P., et al. Liver disease as a major cause of death among HIV infected patients: Role of hepatitis C and B viruses and alcohol J Hepatol 42 2005 799-805.
221. Goedert JJ., Eyster ME., Lederman MM., et al. End-stage liver disease in persons with hemophilia and transfusion-associated infections Blood 100 2002 1584-1589.
222. Lin W., Weinberg EM., Tai AW., et al. HIV increases HCV replication in a TGF-beta-1-dependent manner Gastroenterology 134 2008 803-811.
223. Balagopal A., Philp FH., Astemborski J., et al. Human immunodeficiency virus-related microbial translocation and progression of hepatitis C Gastroenterology 135 2008 226-233.
224. Tuyama A., Hong F., Schecter AD., et al. HIV entry and replication in stellate cells promotes cellular activation and fibrogenesis: Implications for hepatic fibrosis in HIV/HCV co-infection [abstract] Hepatology 46 2007 ALB3.
225. Sterling RK., Contos MJ., Smith PG., et al. Steatohepatitis: Risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection Hepatology 47 2008 1118-1127.
226. Van Den Berg C., Smit C., Van Brussel G., et al. Full participation in harm reduction programs is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: Evidence from the Amsterdam Cohort Studies among drug users Addiction 102 2007 1454-1462.
227. Wicker S., Cinatl J., Berger A., et al. Determination of risk of infection with blood-borne pathogens following a needlestick injury in hospital workers Ann Occup Hyg 52 2008 615-622.
228. Yazdanpanah Y., De Carli G., Migueres B., et al. Risk factors for hepatitis C virus transmission to health care workers after occupational exposure: A European case-control study Clin Infect Dis 41 2005 1423-1430.
229. Chung H., Kudo M., Kumada T., et al. Risk of HCV transmission after needlestick injury, and the efficacy of short-duration interferon administration to prevent HCV transmission to medical personnel J Gastroenterol 38 2003 877-879.
230. Kamal SM., Ismail A., Graham CS., et al. Pegylated interferon alpha therapy in acute hepatitis C: Relation to hepatitis C virus-specific T cell response kinetics Hepatology 39 2004 1721-1731.
231. Kamal SM., Moustafa KN., Chen J., et al. Duration of peginterferon therapy in acute hepatitis C: A randomized trial Hepatology 43 2006 923-931.
232. Kamal SM., Fouly AE., Kamel RR., et al. Peginterferon alfa-2b therapy in acute hepatitis C: Impact of onset of therapy on sustained virologic response Gastroenterology 130 2006 632-638.
233. Davis GL., Nelson DR., Terrault N., et al. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients Liver Transpl 11 2005 941-949.
234. Schiano TD., Charlton M., Younossi Z., et al. Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: Results of a phase 2 randomized study Liver Transpl 12 2006 1381-1389.
235. Wintermeyer P., Wands JR Vaccines to prevent chronic hepatitis C virus infection: Current experimental and preclinical developments J Gastroenterol 42 2007 424-432.
236. Chua BY., Eriksson EM., Brown LE., et al. A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection Vaccine 26 2008 4866-4875.
237. Hadziyannis SJ., Sette H., Morgan TR., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose Ann Intern Med 140 2004 346-355.
238. Soriano V., Maida I., Nunez M., et al. Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies Antivir Ther 9 2004 987-992.
239. Everson GT., Trotter J., Forman L., et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy Hepatology 42 2005 255-262.
240. Formann E., Steindl-Munda P., Hofer H., et al. Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy Aliment Pharmacol Ther 23 2006 507-511.
241. Desmond CP., Roberts SK., Dudley F., et al. Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting J Viral Hepat 13 2006 311-315.
242. Yu ML., Dai CY., Chen SC., et al. High versus standard doses interferon-alpha in the treatment of naive chronic hepatitis C patients in Taiwan: A 10-year cohort study BMC Infect Dis 5 2005 27.
243. Tsuda N., Yuki N., Mochizuki K., et al. Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy J Med Virol 74 2004 406-413.
244. Abdelmalek MF., Firpi RJ., Soldevila-Pico C., et al. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C Liver Transpl 10 2004 199-207.
245. Maylin S M-PM., Moucari R., Boyer N., et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C Gastroenterology 135 2008 821-829.
246. Veldt BJ., Heathcote EJ., Wedemeyer H., et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis Ann Intern Med 147 2007 677-684.
247. Poordad F., Reddy KR., Martin P Rapid virologic response: A new milestone in the management of chronic hepatitis C Clin Infect Dis 46 2008 78-84.
248. Davis GL Monitoring of viral levels during therapy of hepatitis C Hepatology 36 2002 S145-S151.
249. Chung RT., Gale M Jr.., Polyak SJ., et al. Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop Hepatology 47 2008 306-320.
250. Sulkowski M., Lawitz E., Shiffman ML., et al. Final results of the IDEAL (individualized dosing efficacy versus fixed dosing to assess optimal pegylated interferon therapy) phase IIIb study [abstract] J Hepatol 48 2008 A991.
251. Fried MW., Jensen DM., Rodriguez-Torres M., et al. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: Randomized study of higher doses of peginterferon alpha-2a and ribavirin Hepatology 48 2008 1033-1043.
252. Shiffman ML., Salvatore J., Hubbard S., et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha Hepatology 46 2007 371-379.
253. von Wagner M., Huber M., Berg T., et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C Gastroenterology 129 2005 522-527.
254. Mangia A., Santoro R., Minerva N., et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3 N Engl J Med 352 2005 2609-2617.
255. Dalgard O., Mangia A Short-term therapy for patients with hepatitis C virus genotype 2 or 3 infection Drugs 66 2006 1807-1815.
256. Shiffman ML., Suter F., Bacon BR., et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3 N Engl J Med 357 2007 124-134.
257. Yu ML., Dai CY., Huang JF., et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial Hepatology 47 2008 1884-1893.
258. Ferenci P., Laferl H., Scherzer TM., et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response Gastroenterology 135 2008 451-458.
259. Pearlman B., Ehleben C., Saifee S Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders Hepatology 46 2007 1671-1674.
260. Sanchez-Tapias JM., Diago M., Escartin P., et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment Gastroenterology 131 2006 451-460.
261. Mangia A., Minerva N., Bacca D., et al. Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial Hepatology 47 2008 43-50.
262. Zeuzem S., Hultcrantz R., Bourliere M., et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3 J Hepatol 40 2004 993-999.
263. Conjeevaram HS., Fried MW., Jeffers LJ., et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1 Gastroenterology 131 2006 470-477.
264. Jeffers LJ., Cassidy W., Howell CD., et al. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1 Hepatology 39 2004 1702-1708.
265. Muir AJ., Bornstein JD., Killenberg PG Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites N Engl J Med 350 2004 2265-2271.
266. Gross J., Johnson S., Kwo P., et al. Double-dose peginterferon alfa-2b with weight based ribavirin improves response for interferon/ribavirin non-responders with hepatitis C: Final results of “renew” [abstract] Hepatology 42 2005 A60.
267. Everson GT., Hoefs JC., Seeff LB., et al. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial Hepatology 44 2006 1675-1684.
268. Reddy KR., Shiffman ML., Morgan TR., et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment Clin Gastroenterol Hepatol 5 2007 124-129.
269. Shiffman ML., Ghany MG., Morgan TR., et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C Gastroenterology 132 2007 103-112.
270. Fried MW Side effects of therapy of hepatitis C and their management Hepatology 36 2002 S237-S244.
271. Afdhal NH., Dieterich DT., Pockros PJ., et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: A prospective, double-blind, randomized controlled study Gastroenterology 126 2004 1302-1311.
272. Jacobson IM., Gonzalez SA., Ahmed F., et al. A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C Am J Gastroenterol 100 2005 2453-2462.
273. Shiffman ML., Di Bisceglie AM., Lindsay KL., et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment Gastroenterology 126 2004 1015-1023.
274. Taliani G., Gemignani G., Ferrari C., et al. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients Gastroenterology 130 2006 1098-1106.
275. Bacon B., Regev A., Ghalib R., et al. The DIRECT trial (daily-dose consensus interferon and ribavirin: Efficacy of combined therapy): Treatment of non-responders to previous pegylated interfereon plus ribavirin: Sustained virologic response data [abstract] Hepatology 46 2007 A168.
276. Jensen DM., Freilich B., Andreone P., et al. Pegylated interferon alfa-2a (40KD) plus ribavirin (RBV) in prior non-responders to pegylated interferon alfa-2a (12KD)/RBV): Final efficacy and safety outcomes of the repeat study [abstract] Hepatology 46 2007 ALB4.
277. Afdhal N., Levine R., Brown R., et al. Colchicine versus Peg-Interferon alpha 2B long term therapy: Results of the 4 year COPILOT trial [abstract] J Hepatol 48 2008 A3.
278. Pineda JA., Garcia-Garcia JA., Aguilar-Guisado M., et al. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy Hepatology 46 2007 622-630.
279. Chung RT., Andersen J., Volberding P., et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons N Engl J Med 351 2004 451-459.
280. Torriani FJ., Rodriguez-Torres M., Rockstroh JK., et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients N Engl J Med 351 2004 438-450.
281. Carrat F., Bani-Sadr F., Pol S., et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: A randomized controlled trial JAMA 292 2004 2839-2848.
282. Nunez M., Miralles C., Berdun MA., et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: The PRESCO trial AIDS Res Hum Retroviruses 23 2007 972-982.
283. Shea DO., Tuite H., Farrell G., et al. Role of rapid virological response in prediction of sustained virological response to Peg-IFN plus ribavirin in HCV/HIV co-infected individuals J Viral Hepat 15 2008 482-489.
284. Sulkowski MS Viral hepatitis and HIV coinfection J Hepatol 48 2008 353-367.
285. Terrault NA., Berenguer M Treating hepatitis C infection in liver transplant recipients Liver Transpl 12 2006 1192-1204.
286. Lodato F., Berardi S., Gramenzi A., et al. Peg-interferon alfa-2b and ribavirin for the treatment of genotype 1 hepatitis C recurrence after liver transplantation Aliment Pharmacol Ther 28 2008 450-457.
287. Hanouneh IA., Miller C., Aucejo F., et al. Recurrent hepatitis C after liver transplantation: On-treatment prediction of response to peginterferon/ribavirin therapy Liver Transpl 14 2008 53-58.
288. Berenguer M., Palau A., Aguilera V., et al. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation Am J Transplant 8 2008 679-687.
289. Kieffer TL., Sarrazin C., Miller JS., et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients Hepatology 46 2007 631-639.
290. McHutchison JG., Everson GT., Gordon SC., et al. PROVE1: Results from a phase 2 study of telaprevir with peginterferon alpha-2a and ribavirin in treatment-naive subjects with hepatitis C [abstract] J Hepatol 48 2008 A4.
291. Dusheiko GM., Hezode C., Pol S., et al. Treatment of chronic hepatitis C with telaprevir (TVR) in combination with peginterferon-alpha-2a with or without ribavirin: Further interim analysis results of the PROVE2 study [abstract] J Hepatol 48 2008 A58.
292. Kwo P., Lawitz KP., McCone J., et al. Interim resutls from HCV SPRINT-1: RVR/EVR from phase 2 study of boceprevir plus pegintron (peginterferon alpha-2b)/ribavirin in treatment-naive subjects with genotype-1 CHC [abstract] J Hepatol 48 2008 A995.
293. Pockros PJ., Nelson D., Godofsky E., et al. R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin Hepatology 48 2008 385-397.
294. Lalezari J., Gane E., Rodriguez-Torres M., et al. Potent antiviral activity of the HCV nucleoside polymerase inhibitor R7128 500 mg BID for 28 days [abstract] J Hepatol 48 2008 A66.
295. Flisiak R., Feinman SV., Jablkowski M., et al. Efficacy and safety of increasing doses of the cyclophilin inhibitor DEBIO 025 in combination with pegylated interferon alpha-1a in treatment naive chronic HCV patients [abstract] J Hepatol 48 2008 A143.